4D Molecular Therapeutics (4DMT) has received $3 million from Cystic Fibrosis Foundation Therapeutics (CFFT) for development of 4D-710, an aerosolized adeno-associated virus (AAV) gene therapy vector that will deliver a functional copy of the CFTR gene to the lungs of CF patients, the company said.
The funding will be used for completion of studies to support an investigational new drug application with the FDA and for the initiation of clinical trials of 4D-710. CFFT previously made a grant of $525,000 to 4D for development of the product.
4DMT Co-Founder and CEO David Kim commented, “We are very pleased and honored to have been selected to receive additional IND candidate development funding from Cystic Fibrosis Foundation Therapeutics Inc., a world leader in CF research and development. The CF Foundation’s support for our CF product development further validates the potential of our Therapeutic Vector Evolution platform, and the products engineered from our optimized and proprietary AAV vectors. This additional investment will accelerate IND enabling studies and initiation of clinical testing in CF patients with high unmet medical needs.”
Co-Founder and acting Chief Scientific Officer David Schaffer added, “The CFFT is a critical partner for 4DMT’s efforts to bring our transformative gene therapy product to CF patients. In addition to financial support, CFFT clinicians, scientists and patient advocates will work closely with 4DMT to advance 4D-710 as efficiently and effectively as possible.”
Read the 4DMT press release.
